Alfonso G. Zulueta Sells 2,003 Shares of Eli Lilly and Company (LLY) Stock
Eli Lilly and Company (NYSE:LLY) SVP Alfonso G. Zulueta sold 2,003 shares of the company’s stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the sale, the senior vice president now owns 43,580 shares of the company’s stock, valued at $3,646,338.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of Eli Lilly and Company (LLY) opened at $82.49 on Wednesday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. Eli Lilly and Company has a one year low of $64.18 and a one year high of $89.09. The stock has a market cap of $91,236.74, a price-to-earnings ratio of 20.26, a price-to-earnings-growth ratio of 1.83 and a beta of 0.34.
Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The company had revenue of $5.66 billion for the quarter, compared to the consensus estimate of $5.52 billion. During the same period in the previous year, the business earned $0.88 EPS. The company’s revenue was up 9.0% on a year-over-year basis. equities research analysts anticipate that Eli Lilly and Company will post 4.22 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.52%. The ex-dividend date of this dividend is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio (DPR) is currently 98.58%.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/alfonso-g-zulueta-sells-2003-shares-of-eli-lilly-and-company-lly-stock/1704463.html.
Large investors have recently made changes to their positions in the business. Pathstone Family Office LLC raised its stake in Eli Lilly and by 100.0% during the 2nd quarter. Pathstone Family Office LLC now owns 58 shares of the company’s stock valued at $4,774,000 after purchasing an additional 29 shares during the period. Vantage Financial Partners Ltd. Inc. acquired a new position in shares of Eli Lilly and in the second quarter worth $494,000. Acrospire Investment Management LLC increased its stake in shares of Eli Lilly and by 16.7% in the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after acquiring an additional 200 shares during the last quarter. MPS Loria Financial Planners LLC acquired a new position in shares of Eli Lilly and in the second quarter worth $128,000. Finally, San Francisco Sentry Investment Group CA acquired a new position in shares of Eli Lilly and in the second quarter worth $129,000. 75.48% of the stock is currently owned by institutional investors.
LLY has been the subject of a number of research analyst reports. Leerink Swann downgraded Eli Lilly and from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $93.00 to $90.00 in a research report on Wednesday, July 26th. BMO Capital Markets restated an “underperform” rating and issued a $73.00 target price on shares of Eli Lilly and in a research report on Wednesday, July 26th. Oppenheimer Holdings, Inc. downgraded Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 target price for the company. in a research report on Wednesday, July 26th. UBS AG downgraded Eli Lilly and to a “hold” rating and set a $85.00 target price for the company. in a research report on Wednesday, July 26th. Finally, TheStreet upgraded Eli Lilly and from a “c+” rating to a “b+” rating in a research report on Tuesday, July 25th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the stock. Eli Lilly and presently has a consensus rating of “Hold” and an average target price of $89.76.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.